ADC Therapeutics (ADCT) Net Cash Flow (2019 - 2023)
Historic Net Cash Flow for ADC Therapeutics (ADCT) over the last 5 years, with Q4 2023 value amounting to -$32.0 million.
- ADC Therapeutics' Net Cash Flow rose 7713.97% to -$32.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$48.0 million, marking a year-over-year increase of 6566.93%. This contributed to the annual value of -$27.6 million for FY2024, which is 4243.24% up from last year.
- According to the latest figures from Q4 2023, ADC Therapeutics' Net Cash Flow is -$32.0 million, which was up 7713.97% from -$37.0 million recorded in Q3 2023.
- In the past 5 years, ADC Therapeutics' Net Cash Flow ranged from a high of $36.9 million in Q2 2023 and a low of -$139.8 million during Q4 2022
- In the last 5 years, ADC Therapeutics' Net Cash Flow had a median value of -$44769.5 in 2022 and averaged -$15.8 million.
- Data for ADC Therapeutics' Net Cash Flow shows a peak YoY increase of 6849910.29% (in 2023) and a maximum YoY decrease of 85901778.91% (in 2023) over the last 5 years.
- ADC Therapeutics' Net Cash Flow (Quarter) stood at -$34078.0 in 2019, then tumbled by 96372.8% to -$32.9 million in 2020, then soared by 100.48% to $158378.0 in 2021, then crashed by 88376.0% to -$139.8 million in 2022, then skyrocketed by 77.14% to -$32.0 million in 2023.
- Its last three reported values are -$32.0 million in Q4 2023, -$37.0 million for Q3 2023, and $36.9 million during Q2 2023.